Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder

    Summary
    EudraCT number
    		 2011-005200-15
    Trial protocol
    		 DE   FI   SE   NO  
    Global end of trial date
    03 Sep 2013

    Results information
    Results version number
    		 v2
    This version publication date
    10 Jun 2016
    First version publication date
    21 Jan 2015
    Other versions
    		 v1 , v3
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    6096-022
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01554176
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Merck Sharp & Dohme Corp.
    Sponsor organisation address
    2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
    Public contact
    Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
    Scientific contact
    Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Sep 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    03 Sep 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Sep 2013
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant monotherapy with one of identified selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or bupropion. The primary hypothesis of the study is that filorexant is superior to placebo as augmentation therapy with respect to change from baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score. Participants will be randomized to receive filorexant or placebo for a 6-week treatment phase. After completion of the treatment phase, during a 2-week run-out phase participants who received placebo in the treatment phase will continue to receive placebo and those who received filorexant in the treatment phase will receive either filorexant or placebo.
    Protection of trial subjects
    This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
    Background therapy
    		 Participants will continue to take their pretrial antidepressant medication as prescribed throughout the trial.
    Evidence for comparator
    		 -
    Actual start date of recruitment
    18 May 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Norway: 3
    Country: Number of subjects enrolled
    Sweden: 6
    Country: Number of subjects enrolled
    Finland: 15
    Country: Number of subjects enrolled
    France: 19
    Country: Number of subjects enrolled
    Germany: 34
    Country: Number of subjects enrolled
    United States: 52
    Worldwide total number of subjects
    129
    EEA total number of subjects
    77
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    129
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 During the 1-2 week screening period participants will be evaluated to determine if they meet study entry criteria. The screening period will serve as a wash-out period for participants taking prohibited medications.

    Period 1
    Period 1 title
    Treatment Phase
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Filorexant 10 mg (Treatment Phase)
    Arm description
    		 Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    filorexant
    Investigational medicinal product code
    Other name
    MK-6096
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Filorexant, one 10 mg tablet, orally, once daily at bedtime

    Arm title
    		 Placebo (Treatment Phase)
    Arm description
    		 Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
    Arm type
    		 Placebo

    Investigational medicinal product name
    placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo, one tablet, orally, once daily at bedtime

    Number of subjects in period 1
    		Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Started
    65
    64
    Treated
    64
    64
    Completed
    57
    59
    Not completed
    8
    5
         Physician decision
    1
    1
         Consent withdrawn by subject
    1
    -
         Adverse event, non-fatal
    1
    1
         Lost to follow-up
    3
    -
         Not treated: Non-compliance with study drug
    1
    -
         Protocol deviation
    1
    2
         Lack of efficacy
    -
    1
    Period 2
    Period 2 title
    Run-out Phase
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)
    Arm description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
    Arm type
    		 Experimental

    Investigational medicinal product name
    filorexant
    Investigational medicinal product code
    Other name
    MK-6096
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Filorexant, one 10 mg tablet, orally, once daily at bedtime

    Arm title
    		 Filorexant 10 mg/Placebo (Run-out Phase)
    Arm description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
    Arm type
    		 Placebo

    Investigational medicinal product name
    placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo, one tablet, orally, once daily at bedtime

    Arm title
    		 Placebo/Placebo (Run-out Phase)
    Arm description
    		 Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
    Arm type
    		 Placebo

    Investigational medicinal product name
    placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo, one tablet, orally, once daily at bedtime

    Number of subjects in period 2
    		Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) Filorexant 10 mg/Placebo (Run-out Phase) Placebo/Placebo (Run-out Phase)
    Started
    29
    28
    59
    Completed
    29
    27
    59
    Not completed
    0
    1
    0
         Protocol deviation
    -
    1
    -

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Filorexant 10 mg (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.

    Reporting group title
    Placebo (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.

    Reporting group values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase) Total
    Number of subjects
    		 65 64 129
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 47.8 ± 12.4 50 ± 10.3 -
    Gender categorical
    Units: Subjects
        Female
    		 40 42 82
        Male
    		 25 22 47

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Filorexant 10 mg (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.

    Reporting group title
    Placebo (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
    Reporting group title
    Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.

    Reporting group title
    Filorexant 10 mg/Placebo (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.

    Reporting group title
    Placebo/Placebo (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.

    Primary: Change from Baseline to Week 6 in MADRS Total Score

    		 Close Top of page
    End point title
    		 Change from Baseline to Week 6 in MADRS Total Score
    End point description
    The MADRS is a 10-item clinician-rated instrument for evaluating severity of symptoms of depression. Each item is rated on a scale from 0 to 6, with higher scores indicating greater symptom severity. The MADRS total score for each participant was calculated as the sum of the rating assigned to each of the 10 MADRS items, and ranged from 0 to 60 with a higher score indicating greater severity of symptoms. A MADRS total score >30 or 35 indicates severe depression, while a total score ≤10 indicates remission. The reported measure is the change from baseline to Week 6; improvement in symptoms is represented by negative values.
    End point type
    Primary
    End point timeframe
    Baseline and Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    58 [1]
    61 [2]
    Units: score on a scale
    arithmetic mean (standard deviation)
        Baseline
    30.3 ± 4.6
    31 ± 4.3
        Change at Week 6
    -11 ± 9.5
    -10.3 ± 8.2
    Notes
    [1] - Includes participants who took ≥1 dose of study drug and had baseline and Week 6 value
    [2] - Includes participants who took ≥1 dose of study drug and had baseline and Week 6 value
    Statistical analysis title
    		 Change from Baseline in MADRS Total Score - Week 6
    Statistical analysis description
    Number of participants included for calculation of mean ± SD baseline and mean ± SD change from baseline MADRS Total Score is 119. Constrained longitudinal data analysis (cLDA) model uses efficacy Full Analysis Set (FAS) population (number of participants: filorexant 10 mg – 64, placebo – 64; total number of participants in cLDA analysis – 128). FAS includes participants who took ≥1 dose of study drug and had ≥1 evaluable efficacy measurement, including those who had only a baseline measurement.
    Comparison groups
    Filorexant 10 mg (Treatment Phase) v Placebo (Treatment Phase)
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.679 [3]
    Method
    		 Constrained longitudinal data analysis
    Parameter type
    		 Difference in least squares means
    Point estimate
    -0.7
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.8
         upper limit
    		 2.5
    Notes
    [3] - cLDA model included terms for treatment, time, the interaction of time by treatment, severity of disease (Hamilton Depression Rating Scale, 17-items [HAM-D17] ≤20, >20) and insomnia severity index (ISI ≤14, >14).

    Primary: Number of Participants With an Adverse Event (AE) During Treatment Phase

    		 Close Top of page
    End point title
    		 Number of Participants With an Adverse Event (AE) During Treatment Phase
    End point description
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with study drug administration, is also an AE. Participants with one or more AEs during the treatment phase (up to study Week 6) are counted once in this summary.
    End point type
    Primary
    End point timeframe
    Up to Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    64 [4]
    64 [5]
    Units: Participants
    27
    17
    Notes
    [4] - Includes participants who took ≥1 dose of study drug
    [5] - Includes participants who took ≥1 dose of study drug
    Statistical analysis title
    		 Participants with AEs During Treatment Phase
    Statistical analysis description
    Estimated parameter is between-group difference in percentage of participants with an AE = percentage (filorexant 10 mg) − percentage (placebo)
    Comparison groups
    Filorexant 10 mg (Treatment Phase) v Placebo (Treatment Phase)
    Number of subjects included in analysis
    128
    Analysis specification
    Pre-specified
    Analysis type
    		 other [6]
    Method
    		 Miettinen & Nurminen
    Parameter type
    		 Difference in percentage incidence
    Point estimate
    15.6
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.9
         upper limit
    		 31.4
    Notes
    [6] - Between-group comparison of AE incidence rate

    Primary: Number of Participants Who Discontinued Study Drug Due to an AE During Treatment Phase

    		 Close Top of page
    End point title
    		 Number of Participants Who Discontinued Study Drug Due to an AE During Treatment Phase
    End point description
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with study drug administration, is also an AE. Participants who discontinued study drug treatment due to an AE during the treatment phase (up to study Week 6) are counted once in this summary.
    End point type
    Primary
    End point timeframe
    Up to Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    64 [7]
    64 [8]
    Units: participants
    1
    1
    Notes
    [7] - Includes participants who received ≥1 dose of study drug
    [8] - Includes participants who received ≥1 dose of study drug
    Statistical analysis title
    		 Drug Discontinuation Due to AE (Treatment Phase)
    Statistical analysis description
    Estimated parameter is between-group difference in percentage of participants discontinued from study drug due to an AE = percentage (filorexant 10 mg) − percentage (placebo)
    Comparison groups
    Filorexant 10 mg (Treatment Phase) v Placebo (Treatment Phase)
    Number of subjects included in analysis
    128
    Analysis specification
    Pre-specified
    Analysis type
    		 other [9]
    Method
    		 Miettinen & Nurminen
    Parameter type
    		 Difference in percentage incidence
    Point estimate
    0
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -7
         upper limit
    		 7
    Notes
    [9] - Between-group comparison of incidence rate of drug discontinuation due to AE

    Primary: Number of Participants With an AE During Run-out Phase

    		 Close Top of page
    End point title
    		 Number of Participants With an AE During Run-out Phase [10]
    End point description
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with study drug administration, is also an AE. Participants with one or more AEs during the 2-week run-out phase and/or during the 2-week follow up after the last dose of study drug, are counted once in this summary.
    End point type
    Primary
    End point timeframe
    From first run-out dose (following Week 6 visit) up to 14 days after last dose of study drug (approximately 4 weeks)
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was not performed for this endpoint (number of participants with AEs) in run-out phase, as the principal time frame of interest for this measure is the 6-week treatment phase. A statistical analysis is reported for number of participants with AEs in treatment phase.
    End point values
    		 Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) Filorexant 10 mg/Placebo (Run-out Phase) Placebo/Placebo (Run-out Phase)
    Number of subjects analysed
    29 [11]
    28 [12]
    59 [13]
    Units: participants
    6
    3
    9
    Notes
    [11] - Includes participants who took ≥1 dose of study drug in run-out phase
    [12] - Includes participants who took ≥1 dose of study drug in run-out phase
    [13] - Includes participants who took ≥1 dose of study drug in run-out phase
    No statistical analyses for this end point

    Primary: Number of Participants Who Discontinued Study Drug Due to an AE During Run-out Phase

    		 Close Top of page
    End point title
    		 Number of Participants Who Discontinued Study Drug Due to an AE During Run-out Phase [14]
    End point description
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with study drug administration, is also an AE. Participants who discontinued study drug treatment due to an AE during the 2-week run-out phase are counted once in this summary.
    End point type
    Primary
    End point timeframe
    From first run-out dose (following Week 6 visit) up to Week 8 (2 weeks)
    Notes
    [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was not performed for this endpoint (number of participants with study drug discontinuations due to AEs) in run-out phase, as the principal time frame of interest for this measure is the 6-week treatment phase. A statistical analysis is reported for number of participants with study drug discontinuations due to AEs in treatment phase.
    End point values
    		 Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) Filorexant 10 mg/Placebo (Run-out Phase) Placebo/Placebo (Run-out Phase)
    Number of subjects analysed
    29 [15]
    28 [16]
    59 [17]
    Units: participants
    0
    0
    0
    Notes
    [15] - Includes participants who took ≥1 dose of study drug in run-out phase
    [16] - Includes participants who took ≥1 dose of study drug in run-out phase
    [17] - Includes participants who took ≥1 dose of study drug in run-out phase
    No statistical analyses for this end point

    Secondary: Change from Baseline to Week 6 in MADRS Total Score Excluding the Sleep Item

    		 Close Top of page
    End point title
    		 Change from Baseline to Week 6 in MADRS Total Score Excluding the Sleep Item
    End point description
    The MADRS is a 10-item clinician-rated instrument for evaluating severity of symptoms of depression. Each item is rated on a scale from 0 to 6, with higher scores indicating greater symptom severity. The MADRS total score excluding the sleep item for each participant was calculated as the sum of the rating assigned to 9 of the 10 MADRS items (rating for the item “Reduced Sleep” was excluded), and ranged from 0 to 54 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline to Week 6; improvement in symptoms is represented by negative values.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    0 [18]
    0 [19]
    Units: score on a scale
        arithmetic mean (standard deviation)
    ±
    ±
    Notes
    [18] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    [19] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    No statistical analyses for this end point

    Secondary: Change from Baseline to Week 6 in the Hamilton Depression Rating Scale, 17-item Version (HAM-D17) Bech Subscale Score

    		 Close Top of page
    End point title
    		 Change from Baseline to Week 6 in the Hamilton Depression Rating Scale, 17-item Version (HAM-D17) Bech Subscale Score
    End point description
    The HAM-D, an instrument for evaluating severity of symptoms of depression, was completed by the participant. The instrument used in this study was the 17-item version (HAM-D17). Each item is rated on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with higher scores indicating greater symptom severity. The Bech subscale of the HAM-D17 is composed of 6 identified items out of the 17 items rated. The Bech subscale score is the sum for a participant of the 6 items in the subscale, and ranged from 0 to 22 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline to Week 6; improvement in symptoms is represented by negative values.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    0 [20]
    0 [21]
    Units: score on a scale
        arithmetic mean (standard deviation)
    ±
    ±
    Notes
    [20] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    [21] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    No statistical analyses for this end point

    Secondary: Percentage of Participants with HAM-D17 Remission (HAM-D17 Total Score ≤7) at Week 6

    		 Close Top of page
    End point title
    		 Percentage of Participants with HAM-D17 Remission (HAM-D17 Total Score ≤7) at Week 6
    End point description
    The HAM-D, an instrument for evaluating severity of symptoms of depression, was completed by the participant. The instrument used in this study was the 17-item version (HAM-D17). Each item is rated on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with higher scores indicating greater symptom severity. The HAM-D17 total score for each participant was calculated as the sum of the rating assigned to each of the 17 HAM-D items, and ranged from 0 to 54 with a higher score indicating greater severity of symptoms. A participant with HAM-D17 total score ≤7 at Week 6 was defined to have achieved HAM-D17 remission.
    End point type
    Secondary
    End point timeframe
    Week 6
    End point values
    		 Filorexant 10 mg (Treatment Phase) Placebo (Treatment Phase)
    Number of subjects analysed
    0 [22]
    0 [23]
    Units: percentage of participants
    Notes
    [22] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    [23] - Not analyzed: primary efficacy not positive; study ended early with enrollment less than planned
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment Phase: Up to Week 6 Run-out Phase: From first run-out dose (following Week 6 visit) up to 14 days after last dose of study drug (approximately 4 weeks)
    Adverse event reporting additional description
    The 2 treatment phase reporting groups include the total treated study population. The 3 run-out phase groups present those in total treated study population by their randomized assignment during the run-out phase.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    Placebo (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.

    Reporting group title
    Filorexant 10 mg (Treatment Phase)
    Reporting group description
    		 Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.

    Reporting group title
    Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.

    Reporting group title
    Filorexant 10 mg/Placebo (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.

    Reporting group title
    Placebo/Placebo (Run-out Phase)
    Reporting group description
    		 Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the treatment phase.

    Serious adverse events
    		 Placebo (Treatment Phase) Filorexant 10 mg (Treatment Phase) Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) Filorexant 10 mg/Placebo (Run-out Phase) Placebo/Placebo (Run-out Phase)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 64 (1.56%)
    0 / 29 (0.00%)
    0 / 28 (0.00%)
    1 / 59 (1.69%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    Nervous system disorders
    Presyncope
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 64 (0.00%)
    0 / 29 (0.00%)
    0 / 28 (0.00%)
    1 / 59 (1.69%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Diverticulitis
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 64 (1.56%)
    0 / 29 (0.00%)
    0 / 28 (0.00%)
    0 / 59 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Placebo (Treatment Phase) Filorexant 10 mg (Treatment Phase) Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) Filorexant 10 mg/Placebo (Run-out Phase) Placebo/Placebo (Run-out Phase)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    7 / 64 (10.94%)
    13 / 64 (20.31%)
    5 / 29 (17.24%)
    1 / 28 (3.57%)
    3 / 59 (5.08%)
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 64 (0.00%)
    0 / 29 (0.00%)
    0 / 28 (0.00%)
    0 / 59 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    Headache
         subjects affected / exposed
    5 / 64 (7.81%)
    4 / 64 (6.25%)
    1 / 29 (3.45%)
    0 / 28 (0.00%)
    2 / 59 (3.39%)
         occurrences all number
    6
    5
    1
    0
    2
    Somnolence
         subjects affected / exposed
    0 / 64 (0.00%)
    5 / 64 (7.81%)
    1 / 29 (3.45%)
    0 / 28 (0.00%)
    0 / 59 (0.00%)
         occurrences all number
    0
    5
    1
    0
    0
    Psychiatric disorders
    Suicidal ideation
         subjects affected / exposed
    1 / 64 (1.56%)
    5 / 64 (7.81%)
    3 / 29 (10.34%)
    1 / 28 (3.57%)
    1 / 59 (1.69%)
         occurrences all number
    1
    5
    3
    1
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    18 Jun 2012
    Amendment 02: Primary reason for amendment was to incorporate revisions to eligibility criteria and timing of HAM-D assessment at screening.
    14 Dec 2012
    Amendment 03: Primary reason for amendment was to incorporate revisions to eligibility criteria, which were intended to address issue of slow rate of enrollment of participants in the study.

    Interruptions (globally)
    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    25 Jun 2013
    Study recruitment was terminated early due to slow rate of participant enrollment; overall study enrollment planned in protocol was not achieved.
    -

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 17:48:15 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA